Collectively, these findings indicate that the ROCK/MLC/NMMHC IIA-actin loop contributes significantly to ischemic stroke and BBB disruption, and its inhibition represents a novel therapeutic strategy for IS treatment. The gene discussed is MLC1; the disease is ischemic stroke.